Similarly, Goswami et al. [102] demonstrated that TRPV4 genetic ablation or its pharmacologic inhibition blocked ox-LDL-induced macrophage foam cell formation and prevented pathophysiological matrix stiffness, indicating that TRPV4 activation might prevent atherosclerosis progression. This evidence concerns the gene TRPV4 and atherosclerosis.